Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.

Author: BergerBenjamin, DingemanseJasper, KornbergerRüdiger

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the safety and effectiveness of daridorexant, a new drug for insomnia, when taken with citalopram, a common antidepressant. The researchers found that daridorexant and citalopram did not interact significantly in terms of how they were absorbed and processed by the body. However, when taken together, daridorexant's sleep-promoting effects were slightly enhanced. This study suggests that daridorexant can be safely used with citalopram, potentially offering a beneficial treatment option for people with insomnia who also experience depression or anxiety.
Paper Details　
Original Abstract of the Article :
Daridorexant (ACT-541468) is a new dual orexin receptor antagonist being evaluated for the treatment of insomnia, which is a common comorbidity of depression and anxiety. Therefore, daridorexant is likely to be administered concomitantly with agents (e.g., citalopram) used to treat these disorders. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.euroneuro.2021.05.005

データ提供：米国国立医学図書館（NLM）

Daridorexant and Citalopram: A Tale of Two Medications

Insomnia, a common sleep disorder, can be particularly challenging for individuals with depression and anxiety. This research, like a traveler seeking a restful night's sleep in the heart of the desert, explores the potential interactions between daridorexant, a dual orexin receptor antagonist, and citalopram, a selective serotonin reuptake inhibitor (SSRI), commonly prescribed for depression. The study aimed to assess the pharmacokinetic and pharmacodynamic interactions of these medications in healthy subjects.

A Safe Combination: No Major Interactions Found

The study found no significant interactions between daridorexant and citalopram, suggesting that these medications can be safely co-administered. This finding, like a clear desert night sky, suggests that individuals receiving both medications can benefit from their respective therapeutic effects without significant concerns about drug interactions.

A Balanced Approach: Addressing Multiple Needs

The research underscores the importance of considering the potential interactions between medications when treating complex conditions like insomnia, depression, and anxiety. This study, like a desert oasis providing sustenance and respite, provides valuable information for healthcare professionals to make informed decisions regarding medication combinations, ensuring optimal treatment outcomes for patients.

Dr.Camel's Conclusion

This research, like a caravan navigating a complex network of trails, sheds light on the potential interactions between daridorexant and citalopram. The findings suggest that these medications can be safely co-administered, offering a potential solution for individuals facing both insomnia and depression. It's crucial to remember that each individual's response to medication can vary, and further research is necessary to confirm these findings in a broader population.

Date :
  1. Date Completed 2022-04-11
  2. Date Revised 2022-04-11
Further Info :

Pubmed ID

34098518

DOI: Digital Object Identifier

10.1016/j.euroneuro.2021.05.005

Related Literature

Article Analysis
・Effects of daridorexant
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.